In vitro binding of mx2 (krn8602) and epirubicin to human plasma protein

Pharmacology

Volumn 55, Issue 6, 1997, Pages 279-284

  Zhang, Wei Zheng ^a,b   Cosolo, Walter ^b   Zalcberg, John ^b  

^a GEELONG HOSPITAL   (Australia)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

Epirubicin; MX2; Protein binding

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; EPIRUBICIN; PLASMA PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG PROTEIN BINDING; HUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; SCATCHARD PLOT;

EID: 0030727324     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139539     Document Type: Article

References (19)

1. Nobuyasu K. Takashi T. Hamao U: Antitumor activity of new morpho-linoanthracyclines. J Anlibiot 1988: 41:548-553.
2. Bielack SS, Kallenback K. Looft G. Erttmann R. Winkler K: Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance. Anticancer Res 1995:15: 1279-1284.
3. Kiva K. Ogasawara H. Fujita H, Su-giyama K. Kurisu K. Kawamoto K. Uozumi T, Shinkai H: Pharmacokinetics and antitumor activity of MX2. a new morpholino anthracycline in brain tumour intracerebral transplanted in rats. Gan-To-Kaga-ku-Ryoho 1993;20:631-635.
4. Kabuto M. Kubota T. Kodera T: Antitumor effect of MX2. a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro. No-To-Shinkei 1995:47:969-973.
5. Kabuto M. Kubota T. Kobayashi H. Nakagawa T, Kitai R: The antitumor effect ofMX2. a new morpholi-no anthracycline, against malignant glioma cell lines and its subccilular distribution. Neurosurgery 1995:37: 471-477.
6. Yamamoto H. Arila N. Ohnishi T. Hiraga S, Izumoto S. Taki T, Hi-guchi M. Hayakawa T. Shinkai H: Pharmacokinetics of MX2, a new morpholino anthracycline, in CSF following intravenous injection. Gan-To-Kagaku-Ryoho 1993; 20:1227-1230.
7. Watanabe T: State of the art of drug therapy in breast cancer. Gan-To-Kagaku-Ryoho 1993:20:2437-2446.
8. Ohnishi K. Ohno R: New antitumor drugs for malignant lymphoma: a review. Gan-To-Kagaku-Ryoho 1994; 21:1157-1162.
9. Kimura S. Shimada K. Matsuda J. Gohchi K. Fukutake K. Fukue H. Okubo T. Ishigatsubo Y. Yamada K, Koitabashi Y: Phase 111 clinical trial of KRN 8601 (rhG-C'SF) for neutropenia in patients with human immunodeficiency virus infection. Kanscnshogaku-Zasshi 1994: 68:1093-1104.
10. Majima H. Shinkai H: Pharmacokinetics of KRN 8602 in cancer patients. Gan-To-Kagaku-Ryoho 1991:18:2589-2595.
11. Kabuto M, Kubota T. Kobayashi H. Nakagawa T. Arai Y, Kitai R: Sub-cellular localisation and cellular pharmacokinetics of MX2. a new morpholino anthracycline in glioma cells using conlbca! laser scanning microscopy. Neurol Res 1994:16: 257-264.
12. Danks MK. Warmoth MR. Frich E. Granzcn B. Bugg BY. Harkcr WG. Zwclling LA. Futscher BW. Suttlc DP. Beck WT: Single-strand conformational polymorphism analysis of the M(r) 170,000 isoenzyme of DNA topoisomerase II in human tumor cells. Cancer Res 1993:53: 1373-1379.
13. Duran GE, Lau DH. Lewis AD. Kohl JS, Bammler TK, Sikic Bl: Differentia! single-versus double-strand DNA breakage produced by doxorubicin and its morpholinvl analogues. Cancer Chcmother Pharmacol 1996;38:210-216.
14. Ebrahim-el-Zayat AA, Izquierdo MA. Clark GM, Von-Hoff DD: Activity of the morpholine 10-hv-droxycanninomycin (MX2) against human tumour colony-forming units in vitro. Invest New Drags 1995;13:125-131.
15. Benet LZ. Shciner LB: Design and optimisation of dosage regiments; Pharmacokinetic data: in Goodmen LS. Gilman A (cds): The Pharmacological Basis of Therapeutics, ed 7. New York. Macmillan. 1985, pp 1663-1733.
16. Braestrup E: Methods in binding studies; in Enna SJ, Kuhar MJ (cds): Neurotransmitter Receptor Binding. New York. Raven Press, 1978. pp 57-99.
17. Barabas K. Sizensky JA, Faulk WP: Transferrin conjugates of adriamycine are cytotoxic without interacting nuclear DNA. J Biol Chem 1992:267:9437-9442.
18. Oclschlager H: Chemical and pharmacological aspects of benzodiazepines. Schweiz Rundsch Med Prax 1989;78:766-772.
19. Okine L. Gram T: Drug absorption and distribution: in Craig C, Stitzcl R (cds): Modern Pharmacology, ed 2. Boston. Little. Brown, 1986. pp 21-40